BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36408821)

  • 1. Effects of Food and Multiple-dose Administration on the Pharmacokinetic Properties of HR20033, a Sustained-release Formulation of Henagliflozin and Metformin for the Treatment of Diabetes, in Healthy Chinese Volunteers.
    Liu Y; Huyan X; Zhang Q; Qing H; Zhang Q; Wang X; Li Y; Liu Z; Hu W
    Clin Pharmacol Drug Dev; 2023 Apr; 12(4):376-384. PubMed ID: 36408821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Food on the Pharmacokinetic Properties and Mass Balance of Henagliflozin in Healthy Male Volunteers.
    Chen ZD; Chen Q; Zhu YT; Zhang YF; Zhan Y; Chen XF; Liang X; Jia JY; Yu C; Liu HY; Zou JJ; Liu YM; Zhong DF
    Clin Ther; 2021 Sep; 43(9):e264-e273. PubMed ID: 34366153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic Variables of Dapagliflozin/Metformin Extended-release Fixed-dose Combination in Healthy Chinese Volunteers and Regional Comparison.
    Zhao X; Ning R; Hui A; Boulton DW; Tang W
    Clin Ther; 2023 Aug; 45(8):762-769. PubMed ID: 37442656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Henagliflozin, a Novel Selective Inhibitor of Sodium-Glucose Cotransporter 2, in Healthy Subjects Following Single- and Multiple-dose Administration.
    Zhang YF; Liu YM; Yu C; Wang YT; Zhan Y; Liu HY; Zou JJ; Jia JY; Chen Q; Zhong DF
    Clin Ther; 2021 Feb; 43(2):396-409. PubMed ID: 33454124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of drug-drug interaction between henagliflozin, a novel sodium-glucose co-transporter 2 inhibitor, and metformin in healthy Chinese males.
    Wang L; Wu C; Shen L; Liu H; Chen Y; Liu F; Wang Y; Yang J
    Xenobiotica; 2016 Aug; 46(8):703-8. PubMed ID: 26608671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fed and Fasted Single-dose Assessment of Bioequivalence of Dapagliflozin and Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects.
    Boulton DW; Chang M; Griffen SC; Kitaura C; Lubin S; Pollack A; LaCreta F
    Clin Ther; 2016 Jan; 38(1):99-109. PubMed ID: 26682500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and Pharmacodynamic Interactions Between Henagliflozin, a Novel Selective SGLT-2 Inhibitor, and Warfarin in Healthy Chinese Subjects.
    He X; Liu G; Chen X; Wang Y; Liu R; Wang C; Huang Y; Shen J; Jia Y
    Clin Ther; 2023 Jul; 45(7):655-661. PubMed ID: 37451912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No apparent pharmacokinetic interactions were found between henagliflozin: A novel sodium-glucose co-transporter 2 inhibitor and glimepiride in healthy Chinese male subjects.
    Que L; Huang K; Xiang X; Ding Y; Chu N; He Q
    J Clin Pharm Ther; 2022 Aug; 47(8):1225-1231. PubMed ID: 35362180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of food on the pharmacokinetics of gemigliptin/metformin sustained-release 50/1,000 mg (25/500 mg x 2 tablets) fixeddose combination tablet in healthy male volunteers.
    Choi HY; Noh YH; Kim YH; Kim MJ; Lee SH; Kim JA; Kim B; Lim HS; Bae KS
    Int J Clin Pharmacol Ther; 2014 May; 52(5):381-91. PubMed ID: 24495314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
    Kim BH; Shin KH; Kim J; Lim KS; Kim KP; Kim JR; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and Pharmacodynamics of Henagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Chinese Patients with Type 2 Diabetes Mellitus.
    Yong X; Wen A; Liu X; Liu H; Liu YP; Li N; Hu T; Chen Y; Wang M; Wang L; Dai X; Huang J; Li J; Shen H
    Clin Drug Investig; 2016 Mar; 36(3):195-202. PubMed ID: 26692004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of a Lobeglitazone/Metformin Fixed-Dose Combination Tablet (CKD-395 0.5/1000 mg) Versus Concomitant Administration of Single Agents and the Effect of Food on the Metabolism of CKD-395 in Healthy Male Subjects.
    Kim SY; Jeon JY; Park SJ; Kim MG
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):576-584. PubMed ID: 30329224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioequivalence and Pharmacokinetic Evaluation of Two Metformin Hydrochloride Tablets Under Fasting and Fed Conditions in Healthy Chinese Volunteers.
    Huang XM; Wang GZ; He BB; Gao T; Long P; Zhang BK
    Clin Pharmacol Drug Dev; 2020 Nov; 9(8):910-917. PubMed ID: 32936533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Bioavailability of Metformin Hydrochloride Oral Solution Versus Metformin Hydrochloride Tablets in Fasting Mexican Healthy Volunteers.
    Garza-Ocañas L; González-Canudas J; Tamez-de la O E; Badillo-Castañeda C; Gómez-Meza MV; Romero-Antonio Y; Molina-Pérez A; Amador-Hernández AG
    Adv Ther; 2019 Feb; 36(2):407-415. PubMed ID: 30565181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steady-state pharmacokinetics of a novel extended-release metformin formulation.
    Timmins P; Donahue S; Meeker J; Marathe P
    Clin Pharmacokinet; 2005; 44(7):721-9. PubMed ID: 15966755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the Pharmacokinetics of a Fixed-Dose Combination of Rosuvastatin/Metformin Sustained-Release (10/1000 mg) and Separate Tablets in Healthy Male Subjects.
    Huh KY; Kim E; Lee H; Jeon I; Suh H; Lee J; Lee Y; Yu KS; Lee S
    Clin Pharmacol Drug Dev; 2021 Feb; 10(2):207-213. PubMed ID: 32579298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Drug-Drug Interaction Between Henagliflozin and Hydrochlorothiazide in Healthy Chinese Volunteers.
    Chen Q; Yu C; Wu Q; Song R; Liu Y; Feng S; Yu C; Jia J
    Drug Des Devel Ther; 2024; 18():1855-1864. PubMed ID: 38828023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants.
    Murphy J; Wang SS; Stieltjes H; Wajs E; Devineni D
    Int J Clin Pharmacol Ther; 2015 Mar; 53(3):256-64. PubMed ID: 25546166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of fixed-dose combination of atorvastatin and metformin compared with individual tablets.
    Ghim JL; Phuong NTT; Kim MJ; Kim EJ; Song GS; Ahn S; Shin JG; Kim EY
    Drug Des Devel Ther; 2019; 13():1623-1632. PubMed ID: 31190741
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetics of a fixed-dose combination of atorvastatin and metformin extended release versus concurrent administration of individual formulations: a randomized, open-label, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study.
    Kandhwal K; Dey S; Nazarudheen S; Arora R; Reyar S; Thudi NR; Monif T; Singh MK; Rao S
    Clin Drug Investig; 2011 Dec; 31(12):853-63. PubMed ID: 21919543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.